One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines

Journal of Clinical Research

Volumn 7, Issue 1-20, 2004, Pages 1-20

  Carruthers, Alastair ^a,e   Carruthers, J ^a   Lowe, N J ^b   Menter, A ^c   Gibson, J ^d   Nordquist, M ^d   Mordaunt, J ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Clinical Research Specialists   (Canada)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d ALLERGAN INC   (United States)

^e Carruthers Dermatology Center   (Canada)

Author keywords

BOTOX Cosmetic; Botulinum toxin type A; Glabellar lines

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ACNE; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ECCHYMOSIS; ESTHETICS; FACE PAIN; FLU LIKE SYNDROME; GLABELLAR LINE; HEADACHE; HUMAN; INJECTION; INJECTION SITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; PTOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME;

EID: 3042523236     PISSN: 13695207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 2002 National Totals for Cosmetic Procedures. American Society for Aesthetic Plastic Surgery for Statistical data. Available at: http://www.surgery.org/press/national_totals.pdf. Accessed September 29, 2003.
2. Bell MS, Vermeulen LC, Sperling KB. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. Pharmacotherapy 2000; 20: 1079-1091.
3. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743-1746.
4. American Academy of Neurology Therapeutics and Technology Assessment Subcommittee. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology 1994; 44: 2401-2403.
5. Sutherland DH, Kaufman KR, Wyatt MP et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999; 10: 1-9.
6. Flett PJ, Stem LM, Waddy H et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. Journal of Paediatrics and Child Health 1999; 35: 71-77.
7. Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-1310.
8. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomised, double-blind, placebo-controlled trial. Clinical Rehabilitation 1998; 12: 381-388.
9. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. British Medical Journal 2001; 323: 596-599.
10. Silberstein S, Mathew N, Saper J, Jenkins S for the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000; 40: 445-450.
11. Klapper JA, Klapper A. Use of botulinum toxin in chronic daily headaches associated with migraine. Headache Quarterly 1999; 10: 141-143.
12. Smuts JA, Baker MK, Smuts M et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. European Journal of Neurology 1999; 6: S99-S102.
13. Relja M. Treatment of tension-type headaches by local injection of botulinum toxin. European Journal of Neurology 1997; 4: S71-S73.
14. Jankovic J, Hallett M, Editors. Therapy With Botulinum Toxin. New York: Marcel Dekker, Inc., 1994.
15. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Movement Disorders 1994; 9: 213-217.
16. Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomised, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology 2002; 46: 840-849.
17. Carruthers D, Lowe NJ, Menter MA et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A in patients with glabellar lines. Journal of Plastic and Reconstruction Surgery 2003; 112: 1089-1098.
18. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J and Hallett M, Eds. Therapy With Botulinum Toxin. New York: Marcel Dekker, Inc, 1994: 93-107.
19. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55: S22-S28.
20. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. Journal of the American Academy of Dermatology 1996; 35: 569-572.
21. Carruthers A, Carruthers JA. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallett M, Eds. Therapy With Botulinum Toxin. New York, NY: Marcel Dekker, Inc 1994: 577-595.
22. Blitzer A, Binder WJ, Aviv JE et al. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Archives of Otolaryngology - Head and Neck Surgery 1997; 123: 389-392.
23. Guerrissi J, Sarkissian P. Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines. Annals of Plastic Surgery 1997; 39: 447-453.